コメントを投稿するにはログインが必要です
ログインページへ記事ができると、章ごとの要約と、聴きどころへ飛べる目次がここに並びます。いまは音声で聴けます。
#4-35E. Optimizing Perinatal RA Care: Lower Postpartum Flare Rates (Mod Rheumatol, 2026)
2026年5月8日 05:00·4分56秒
How can we effectively prevent postpartum flares in pregnant women with rheumatoid arthritis (RA)? This episode delves into a retrospective observational study utilizing a Japanese claims database to investigate peri-delivery RA prescription trends. The researchers discovered that only 22.4% of deliveries required the initiation or resumption of intensive treatments, such as biologic DMARDs or methotrexate, in the postpartum period. This crucial clinical finding indicates that appropriate medication management throughout pregnancy, strongly aligned with the latest evidence-based guidelines, contributes significantly to maintaining stable disease control after delivery. However, when critically appraising this study, listeners must consider its reliance on claims data; specifically, the absence of clinical disease activity indices like the DAS28-CRP score means that prescription modifications were utilized as a proxy for actual disease exacerbation. Despite this methodological limitation, this paper is highly relevant and practical for physicians, as it underscores the vital role of meticulous preconception care and strategic treatment planning to ensure optimal long-term outcomes for RA patients desiring to conceive.
Citation: Yuichi Shiotsuki, Miho Iida, Shiori Tsuchiya, Minako Matsumoto, Daisuke Sugiyama. Changes in rheumatoid arthritis medication in pregnancy: a retrospective observational study using a Japanese claims database. Modern Rheumatology. 2026. DOI: 10.1093/mr/roaf106
Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.
